{"id":75361,"date":"2026-08-19T17:32:14","date_gmt":"2026-08-19T09:32:14","guid":{"rendered":"https:\/\/flcube.com\/?p=75361"},"modified":"2026-08-19T17:32:15","modified_gmt":"2026-08-19T09:32:15","slug":"haisco-pharmaceutical-wins-nmpa-clinical-approval-for-nav1-8-inhibitor-hsk51155-pain-drug-licensed-to-abbvie-in-usd-700-million-deal-advances-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75361","title":{"rendered":"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China-based <strong>Haisco Pharmaceutical Group Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/002653:SHE\">SHE: 002653<\/a>) announced receiving <strong>clinical approval<\/strong> for its pain relief drug <strong>HSK51155<\/strong> from the <strong>National Medical Products Administration (NMPA)<\/strong>, advancing the <strong>Nav1.8 inhibitor<\/strong> into clinical trials months after it was licensed to <strong>AbbVie<\/strong> in a blockbuster deal.<\/p>\n\n\n\n<h2 id=\"h-approval-summary\" class=\"wp-block-heading\">Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Haisco Pharmaceutical Group Co., Ltd (SHE: 002653)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>HSK51155<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td><strong>Nav1.8 inhibitor<\/strong> (selective sodium ion channel blocker)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Pain relief<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Clinical approval granted by <strong>NMPA<\/strong><\/td><\/tr><tr><td><strong>Licensing Partner<\/strong><\/td><td>AbbVie (April 2026 deal, potential total value <strong>&gt; USD 700 million<\/strong>)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>19 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-hsk51155\" class=\"wp-block-heading\">Drug Profile \u2013 HSK51155<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> A <strong>Nav1.8 inhibitor<\/strong> that selectively blocks specific sodium ion channels<\/li>\n\n\n\n<li><strong>Pharmacology:<\/strong> Suppresses <strong>abnormal firing of pain\u2011sensing nerves<\/strong> and reduces <strong>pain signal transmission<\/strong><\/li>\n\n\n\n<li><strong>Positioning:<\/strong> Selective Nav1.8 inhibition is a sought\u2011after approach in non\u2011opioid analgesic development, aiming to deliver pain relief without the central side effects associated with conventional analgesics<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-abbvie-licensing-deal-background\" class=\"wp-block-heading\">AbbVie Licensing Deal Background<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Deal Date<\/strong><\/td><td>April 2026<\/td><\/tr><tr><td><strong>Assets<\/strong><\/td><td>HSK51155 + another analgesic candidate<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>AbbVie<\/td><\/tr><tr><td><strong>Potential Total Value<\/strong><\/td><td>Exceeding <strong>USD 700 million<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The NMPA clinical approval marks a key execution milestone under the partnership, validating the development path of the asset <strong>AbbVie<\/strong> chose to license.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non\u2011Opioid Analgesia Race:<\/strong> Nav1.8 inhibitors are among the most closely watched mechanisms in the hunt for effective non\u2011opioid pain therapies, a market with enormous unmet need in both China and the U.S.<\/li>\n\n\n\n<li><strong>Deal Validation:<\/strong> Clinical clearance in China de\u2011risks the program backing <strong>Haisco Pharmaceutical&#8217;s<\/strong> USD 700 million\u2011plus <strong>AbbVie<\/strong> partnership, strengthening confidence in the pipeline that attracted one of the world&#8217;s largest immunology and neuroscience players.<\/li>\n\n\n\n<li><strong>Global\u2011China Dual Track:<\/strong> With AbbVie holding licensed rights and Haisco advancing its own NMPA\u2011cleared trials, HSK51155 now has parallel development pathways that could accelerate global readouts.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> First\u2011in\u2011human safety and pharmacokinetic data, trial design for pain indications, and AbbVie&#8217;s global development timeline for the licensed program.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development, regulatory outcomes, and commercial expectations for HSK51155. Actual results may differ due to risks including early\u2011stage clinical uncertainty, regulatory decisions, and competitive dynamics in analgesic drug development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK51155\u7247\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK51155\u7247\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-a140121f-0fe7-49fe-a334-af6e3ac6e7a3\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK51155\u7247\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\">\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK51155\u7247\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/\u6d77\u601d\u79d1\uff1a\u5173\u4e8e\u83b7\u5f97\u521b\u65b0\u836fHSK51155\u7247\u300a\u836f\u7269\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u300b\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a140121f-0fe7-49fe-a334-af6e3ac6e7a3\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving clinical approval for its pain&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,139,929],"class_list":["post-75361","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-haisco-pharmaceutical","tag-she-002653"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving clinical approval for its pain relief drug HSK51155 from the National Medical Products Administration (NMPA), advancing the Nav1.8 inhibitor into clinical trials months after it was licensed to AbbVie in a blockbuster deal.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75361\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China\" \/>\n<meta property=\"og:description\" content=\"China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving clinical approval for its pain relief drug HSK51155 from the National Medical Products Administration (NMPA), advancing the Nav1.8 inhibitor into clinical trials months after it was licensed to AbbVie in a blockbuster deal.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75361\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-19T09:32:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-19T09:32:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75361#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75361\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China\",\"datePublished\":\"2026-08-19T09:32:14+00:00\",\"dateModified\":\"2026-08-19T09:32:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75361\"},\"wordCount\":383,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Haisco Pharmaceutical\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75361#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75361\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75361\",\"name\":\"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-19T09:32:14+00:00\",\"dateModified\":\"2026-08-19T09:32:15+00:00\",\"description\":\"China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving clinical approval for its pain relief drug HSK51155 from the National Medical Products Administration (NMPA), advancing the Nav1.8 inhibitor into clinical trials months after it was licensed to AbbVie in a blockbuster deal.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75361#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75361\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75361#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving clinical approval for its pain relief drug HSK51155 from the National Medical Products Administration (NMPA), advancing the Nav1.8 inhibitor into clinical trials months after it was licensed to AbbVie in a blockbuster deal.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75361","og_locale":"en_US","og_type":"article","og_title":"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China","og_description":"China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving clinical approval for its pain relief drug HSK51155 from the National Medical Products Administration (NMPA), advancing the Nav1.8 inhibitor into clinical trials months after it was licensed to AbbVie in a blockbuster deal.","og_url":"https:\/\/flcube.com\/?p=75361","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-19T09:32:14+00:00","article_modified_time":"2026-08-19T09:32:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75361#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75361"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China","datePublished":"2026-08-19T09:32:14+00:00","dateModified":"2026-08-19T09:32:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75361"},"wordCount":383,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Haisco Pharmaceutical","SHE: 002653"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75361#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75361","url":"https:\/\/flcube.com\/?p=75361","name":"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-19T09:32:14+00:00","dateModified":"2026-08-19T09:32:15+00:00","description":"China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving clinical approval for its pain relief drug HSK51155 from the National Medical Products Administration (NMPA), advancing the Nav1.8 inhibitor into clinical trials months after it was licensed to AbbVie in a blockbuster deal.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75361#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75361"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75361#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 \u2013 Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75361"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75361\/revisions"}],"predecessor-version":[{"id":75363,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75361\/revisions\/75363"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}